What are the symptoms and treatment of angioedema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms and Treatment of Angioedema

Clinical Presentation of Angioedema

Angioedema manifests as localized, non-pitting swelling of the subcutaneous or submucosal tissues that develops suddenly and can be life-threatening when it involves the upper airway. 1

Key Symptoms by Location

Cutaneous and Mucosal Swelling:

  • Periorbital swelling, lip swelling, and tongue enlargement are the most common presentations 2
  • Extremity swelling that can be disabling but not life-threatening 1
  • Genitourinary involvement causing severe discomfort and potential urinary retention 1

Oropharyngeal and Laryngeal Symptoms (Life-Threatening):

  • Change in voice quality 1, 3
  • Loss of ability to swallow 1, 3
  • Difficulty breathing or sensation of throat tightness 1, 3
  • These symptoms carry historical mortality rates of approximately 30% or higher if untreated 4

Abdominal Symptoms:

  • Severe abdominal pain requiring narcotic analgesia 1
  • Nausea and vomiting requiring antiemetics 1
  • Third-space fluid sequestration necessitating aggressive hydration 1

Distinguishing Features:

  • Angioedema typically occurs WITHOUT urticaria (hives) in approximately 50% of cases, though concomitant urticaria suggests histamine-mediated disease 2, 5
  • Pruritus (itching) suggests allergic/histaminergic origin 5
  • Attacks may be preceded by premonitory signs (prodromes) 1

Treatment Algorithm Based on Angioedema Type

Immediate Assessment (All Types)

Airway evaluation is the absolute first priority regardless of angioedema type. 4, 3

  • Monitor for signs of impending airway closure: voice change, inability to swallow, dyspnea 1, 3
  • All patients with oropharyngeal or laryngeal involvement must be observed in a facility capable of emergency intubation or tracheostomy 1, 3
  • Consider elective intubation early if airway compromise signs develop, as anatomy becomes highly distorted 1, 3
  • Avoid direct airway visualization unless absolutely necessary, as trauma can worsen swelling 1, 3
  • Have backup tracheostomy immediately available 3

Histamine-Mediated (Allergic) Angioedema

For allergic angioedema with significant symptoms or airway involvement, administer epinephrine 0.3 mL of 0.1% solution subcutaneously or 0.5 mL by nebulizer immediately. 3, 6

Additional first-line therapy:

  • IV diphenhydramine 50 mg 3
  • IV methylprednisolone 125 mg 3
  • H2 blockers: ranitidine 50 mg IV or famotidine 20 mg IV 3

For chronic histamine-mediated angioedema:

  • High-dose second-generation H1 antihistamines (fourfold the standard dose) 4
  • Add montelukast if antihistamines alone fail 4

Hereditary Angioedema (HAE) - Bradykinin-Mediated

Critical: Standard allergic treatments (epinephrine, antihistamines, corticosteroids) are NOT effective for HAE and represent a common emergency department error. 4, 3, 7

First-line on-demand treatments (choose one):

  • Plasma-derived C1 inhibitor (pdC1INH): 1000-2000 U intravenously 1, 4, 3, 7
  • Icatibant: 30 mg subcutaneously 1, 4, 3, 7
  • Ecallantide: administered by healthcare provider within 8 hours of attack onset 1, 4
  • Recombinant human C1 inhibitor (rhC1INH): intravenous administration 1

If specific therapies unavailable:

  • Fresh frozen plasma 10-15 mL/kg may be considered, though it carries risk of paradoxical worsening due to providing additional contact system substrates 1, 3
  • Be prepared to manage potential exacerbation of symptoms with fresh frozen plasma 1

Emerging oral therapies:

  • Sebetralstat (oral plasma kallikrein inhibitor) has completed Phase 3 trials 1
  • Deucrictibant (oral bradykinin B2 receptor antagonist) is in Phase 3 trials 1

ACE Inhibitor-Induced Angioedema

Immediately and permanently discontinue the ACE inhibitor - this is non-negotiable. 3, 7

Acute management:

  • Bradykinin-targeted therapies: icatibant 30 mg subcutaneously 3, 7
  • Fresh frozen plasma only if icatibant or C1 inhibitor unavailable 7
  • Standard allergic treatments (antihistamines, corticosteroids, epinephrine) are ineffective 4, 3

Long-term considerations:

  • Never restart any ACE inhibitor (class effect) 7
  • Switching to ARB carries 2-17% recurrence risk, though most patients tolerate ARBs 7
  • African Americans, smokers, older individuals, and females are at higher risk 3

Symptomatic Management by Location

Abdominal Attacks:

  • Narcotic analgesics for severe pain (avoid chronic opioid use - addiction risk) 1, 3
  • Antiemetics for nausea/vomiting 1, 7
  • Aggressive IV hydration for third-space fluid losses 1, 7
  • Avoid out-of-hospital potent narcotics (fentanyl patches, oxycodone) 1

Extremity Attacks:

  • No specific symptomatic therapy available 1

Genitourinary Attacks:

  • Pain medication as needed 1
  • Urinary catheterization if unable to void 1

Prophylaxis Strategies for HAE

Short-term prophylaxis (before dental/surgical procedures):

  • Plasma-derived C1 inhibitor 1000-2000 U intravenously 4, 7
  • Androgens (danazol 2.5-10 mg/kg) 7

Long-term prophylaxis (for frequent attacks):

  • Androgens: danazol 100 mg on alternate days 4, 7
  • Antifibrinolytic agents: tranexamic acid 30-50 mg/kg/day 7
  • For children where first-line agents unavailable: tranexamic acid preferred 3
  • For pregnant patients: C1-INH is the only recommended acute and prophylactic treatment 3

Critical Pitfalls to Avoid

The most dangerous error is treating bradykinin-mediated angioedema (HAE or ACE inhibitor-induced) with standard allergic therapies - these are completely ineffective and waste critical time. 4, 3, 7

  • Do not delay epinephrine in true allergic angioedema with airway compromise 3
  • Do not discharge patients with oropharyngeal/laryngeal involvement without adequate observation 3
  • Do not use chronic potent opioids for HAE patients with frequent attacks 3
  • Androgens and antifibrinolytic drugs are NOT effective for acute attacks (require days to work) 1
  • Do not directly visualize the airway unless absolutely necessary 1, 3

Diagnostic Clues for Differentiation

Timing:

  • Allergic angioedema develops rapidly (minutes) 5
  • Bradykinin-mediated angioedema develops slowly (hours) 5

Associated features:

  • Urticaria + pruritus = histamine-mediated 5
  • No urticaria, slower onset = consider bradykinin-mediated 5

Medication history:

  • ACE inhibitors can cause angioedema even after years of use 4

Family history:

  • Positive family history suggests HAE 4, 2

Laboratory confirmation (when time permits):

  • Measure C4, C1INH antigen, and C1INH function to exclude C1INH deficiency 4
  • If acquired C1INH deficiency suspected: measure C1q level and anti-C1INH antibodies 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Treatment for Angioedema

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Angioedema

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The spectrum and treatment of angioedema.

The American journal of medicine, 2008

Guideline

Treatment of Angioedema

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.